Background: Theepidemiologic features of status epilepticus (SE) are still in the course of definition. Methods: We carried out an intensive survey of multiple sources of case material in the resident population of the health district of Ferrara, Italy, in 2003. Information was collected on age, gender, duration, seizure type and etiology of SE. Results: The age- adjusted annual incidence rate of SE was 27.2/100,000 (95% CI = 19.4–36.9) and it was higher in men (41.7/100,000, 95% CI = 26.9–61.7) than in women (12.3/100,000, 95% CI = 6.9–20.4). The incidence was higher in the elderly (older than 60 years, 39.2/100,000) than in younger adults in the age group 20–59 years (14.7/100,000). The age-specific incidence showed a bimodal distribution peaking in the youngest (0–4 years) and in the oldest age group (75+ years). Cerebrovascular disease was the most frequent etiologic factor (45%). Epilepsy had previously been diagnosed in 40% of the patients. The case fatality was 5%. Conclusions: The study found a higher incidence of SE than that expected on the basis of the previous European studies suggesting that the risk of SE in southern Europe is higher and more similar to that estimated in population studies in the United States. The case fatality was lower than that reported in previous South-European population studies despite the similar clinical features of the patients. Indirect evidence suggests that several factors related to the SE management could have positively influenced the outcome.

Keywords:
Status epilepticus, incidence, Case fatality ratio
1.
Vignatelli L, Tonon C, D’Alessandro R; Bologna Group for the Study of Status Epilepticus: Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy. Epilepsia 2003;44:964–968.
2.
Coeytaux A, Jallon P, Galobardes B, Morabia A: Incidence of status epilepticus in French-speaking Switzerland (EPISTAR). Neurology 2000;55:693–697.
3.
Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, Katsarou N, Hamer HM; Status Epilepticus Study Group Hessen (SESGH): Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001;42:714–718.
4.
Vignatelli L, Rinaldi R, Galeotti M, de Carolis P, D’Alessandro R: Epidemiology of status epilepticus in a rural area of northern Italy: a 2-year population-based study. Eur J Neurol 2005;12:897–902.
5.
Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA: Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998;50:735–741.
6.
DeLorenzo J, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, Garnett L, Fortner CA, Ko D: A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029–1035.
7.
Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA: Short-term mortality after a first episode of status epilepticus. Epilepsia 1997;38:1344–1349.
8.
Govoni V, Fallica E, Monetti VC, Guerzoni F, Faggioli R, Casetta I, Granieri E: Incidence and short-term prognosis of status epilepticus in the health district of Ferrara, Italy, in 2003. Neurol Sci 2005;26(suppl):139–140.
9.
Govoni V, Granieri E, Capone J, Manconi M, Casetta I: Amyotrophic lateral sclerosis in the local health district of Ferrara, Italy, 1964–1998. Neuroepidemiology 2003;22:229–234.
10.
Govoni V, Granieri E, Manconi M, Capone J, Casetta I: Is there a decrease in Guillain-Barré syndrome after bovine ganglioside withdrawal in Italy? A population-based study in the local health district of Ferrara, Italy. J Neurol Sci 2003;216:99–103.
11.
Govoni V, Granieri E, Fallica E, Casetta I: Amyotrophic lateral sclerosis, rural environment and agricultural work in the local health district of Ferrara, Italy, in the years 1964–1998. J Neurol 2005;252:1322–1327.
12.
Commission on Epidemiology and Prognosis, International League against Epilepsy: Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:592–596.
13.
Hauser WA, Annegers JF, Kurland LT: Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993;34:453–468.
14.
Waterhause J, Muir C, Shanmungaratham K, Powel J: Cancer incidence in five continents. IARC Sci Publ 1982;4:673.
15.
Schoenberg BS: Calculating confidence intervals for rates and ratios. Neuroepidemiology 1983;2:257–265.
16.
Rothman KJ: Modern Epidemiology. Boston, Little, Brown and Company, 1986, pp 1–358.
17.
Breslow NE, Day NE: Statistical Methods in Cancer Research. Lyon, International Agency for Research on Cancer, 1987, vol 2: The Design and Analysis of Cohort Studies, pp 58–61.
18.
Towne AR, Waterhouse EJ, Boggs JG, Garnett LK, Brown AJ, Smith JR, DeLorenzo RJ: Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000;54:340–345.
19.
Treinman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE, Mamdani MB: A comparison of four treatment for generalized convulsive status epilepticus. N Engl J Med 1998;339:792–798.
20.
Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B: Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983;249:1452–1454.
21.
Hauser WA, Hesdorffer DC: Epilepsy: Frequency, Causes and Consequences. New York, Demos, 1990.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.